Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick G Morris

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Anti-Cancer Drugs|March 13, 2012
Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?Patrick G Morris
Anti-Cancer Drugs|September 15, 2010
Advances in therapy: eribulin improves survival for metastatic breast cancerPatrick G Morris
The Lancet. Neurology|May 19, 2009
Therapeutic challenges in primary CNS lymphomaPatrick G Morris, Lauren E Abrey
Expert Opinion on Pharmacotherapy|May 28, 2013
Identifying the challenges of biomarkers that predict response to HER2-directed therapiesNeil M Iyengar, Patrick G Morris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Microtubule active agents: beyond the taxane frontierPatrick G Morris, Monica N Fornier
Targeted Oncology|September 17, 2010
Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomasPatrick G Morris, Lauren E Abrey
Expert Review of Anticancer Therapy|February 6, 2009
Novel anti-tubulin cytotoxic agents for breast cancerPatrick G Morris, Monica N Fornier
Critical Reviews in Oncology/Hematology|March 16, 2010
Optimizing the use of anthracyclines in older patients with breast cancerPatrick G Morris, Monica N Fornier
Anti-Cancer Drugs|July 25, 2012
Recent advances in novel targeted therapies for HER2-positive breast cancerConleth G Murphy, Patrick G Morris
International Journal of Women'S Health|November 13, 2010
Aromatase inhibitor strategies in metastatic breast cancerHeather L McArthur, Patrick G Morris
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Anti-Cancer Drugs|March 13, 2012
Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?Patrick G Morris
Anti-Cancer Drugs|September 15, 2010
Advances in therapy: eribulin improves survival for metastatic breast cancerPatrick G Morris
The Lancet. Neurology|May 19, 2009
Therapeutic challenges in primary CNS lymphomaPatrick G Morris, Lauren E Abrey
Expert Opinion on Pharmacotherapy|May 28, 2013
Identifying the challenges of biomarkers that predict response to HER2-directed therapiesNeil M Iyengar, Patrick G Morris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Microtubule active agents: beyond the taxane frontierPatrick G Morris, Monica N Fornier
Targeted Oncology|September 17, 2010
Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomasPatrick G Morris, Lauren E Abrey
Expert Review of Anticancer Therapy|February 6, 2009
Novel anti-tubulin cytotoxic agents for breast cancerPatrick G Morris, Monica N Fornier
Critical Reviews in Oncology/Hematology|March 16, 2010
Optimizing the use of anthracyclines in older patients with breast cancerPatrick G Morris, Monica N Fornier
Anti-Cancer Drugs|July 25, 2012
Recent advances in novel targeted therapies for HER2-positive breast cancerConleth G Murphy, Patrick G Morris
International Journal of Women'S Health|November 13, 2010
Aromatase inhibitor strategies in metastatic breast cancerHeather L McArthur, Patrick G Morris
Pageof 10